11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one |
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody) |
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one |
11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one |
11-cyclopropyl-4-methyl-5H-dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one |
11-Cyclopropyl-4-methyl-5H-dipyrido[3,2-b |
11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE |
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one |
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[2,3-B:3',2'-E][1,4]DIAZEPIN-6-ONE |
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one |
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one |
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B',3'-E][1,4]DIAZEPIN-6-ONE |
129618-40-2 |
1vrt |
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one |
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0;{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one |
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3,8)]PENTADECA-1(11),3,5,7,12,14-HEXAEN-10-ONE |
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3,5,7,12,14-HEXAEN-10-ONE |
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,12,14-HEXAEN-10-ONE |
2-CYCLOPROPYL-7-METHYL-2,4,9,15-TETRAAZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(15),3(8),4,6,11,13-HEXAEN-10-ONE |
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0(3),]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one |
2hny |
5-Cyclopropyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one |
5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl- |
618N402 |
6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- |
6H-DIPYRIDO[2,3-B:3',2'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL- |
6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- |
6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL- |
99DK7FVK1H |
AB0013383 |
AB00393001_16 |
AB00393001_17 |
AB00393001-13 |
AB00393001-15 |
AB07544 |
AB2000266 |
AC-643 |
AC1L1I81 |
AJ-08226 |
AK143126 |
AKOS005504351 |
ALBB-027264 |
AN-15635 |
BBL010768 |
BC206673 |
BDBM1434 |
BI RG 587 |
BI-RG 587 |
BI-RG-587 |
BI-RG-587 & CD4-IgG |
BIDD:GT0326 |
Bio-0789 |
BIRG 0587 |
BIRG 587 |
BIRG-0587 |
BIRG-587 |
BIRG587 |
C07263 |
C15H14N4O |
Cahill May Roberts Brand of Nevirapine |
CAS-129618-40-2 |
CCG-100939 |
CHEBI:63613 |
CHEMBL57 |
CPD000048458 |
CS-2252 |
CTK8E7455 |
D00435 |
D0O2EM |
DB00238 |
DR000811 |
DSSTox_CID_10787 |
DSSTox_GSID_31797 |
DSSTox_RID_78889 |
DTXSID7031797 |
F2173-0607 |
FT-0607215 |
H954 |
HMS2051J09 |
HMS2231O23 |
HMS3264D21 |
HMS3371E03 |
HMS3393J09 |
HMS3655I08 |
HSDB 7164 |
HY-10570 |
I02-0310 |
KB-64802 |
KS-00000KZF |
KS-5019 |
LS-2289 |
MCULE-8608154492 |
MFCD00866928 |
MLS000084585 |
MLS000759409 |
MLS001055309 |
MLS001201730 |
MLS001424058 |
MLS006011423 |
MolPort-002-507-817 |
N0922 |
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin |
NC00189 |
NCGC00065890-02 |
NCGC00065890-03 |
NCGC00065890-04 |
NCGC00065890-05 |
NCGC00065890-07 |
NCGC00258324-01 |
NEV |
NEVARAPINE |
nevirapine |
Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard |
Nevirapine (JAN/USP/INN) |
Nevirapine (Viramune) |
Nevirapine [USAN:INN] |
Nevirapine [USAN:USP:INN:BAN] |
Nevirapine & CD4-IgG |
Nevirapine & PRO 140 |
Nevirapine anhydrous |
Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard |
Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard |
Nevirapine solution, 1.0 mg/mL in methanol, certified reference material |
Nevirapine, pharmaceutical secondary standard; traceable to USP, PhEur |
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE |
NQDJXKOVJZTUJA-UHFFFAOYSA-N |
NSC 641530 |
NSC-641530 |
NSC-759902 |
NSC641530 |
NSC759902 |
NVP |
Opera_ID_934 |
Pharmakon1600-01503842 |
PL004639 |
PL040500 |
PL044148 |
Promeco Brand of Nevirapine |
R3924 |
RL01415 |
RT-014690 |
S1742 |
SAM001246551 |
SC-17266 |
SCHEMBL3318 |
SMR000048458 |
ST24038235 |
STK580320 |
Tox21 110982 |
Tox21_110982 |
Tox21_110982_1 |
Tox21_200770 |
UNII-99DK7FVK1H |
Viramune |
Viramune (TN) |
Viramune IR |
Viramune, BI-RG 587, Nevirapine |
Viramune;BI-RG 587 |
Viramune(TM) |
Z1695906730 |
ZB000592 |
ZINC4778 |